AstraZeneca PLC ADR (AZN) News
Filter AZN News Items
AZN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AZN News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest AZN News From Around the Web
Below are the latest news stories about ASTRAZENECA PLC that investors may wish to consider to help them evaluate AZN as an investment opportunity.
3 Cheap Growth Stocks to Buy in 2025As we enter 2025, many growth stocks are trading at high valuations and could be running out of room to rise in the near term. For long-term investors, now may be a good time to reevaluate the contents of your portfolio to see if it's worth potentially selling off some of your recent high performers and swapping in some cheaper growth stocks instead. Three growth stocks that look particularly cheap right now are AstraZeneca (NASDAQ: AZN), Uber Technologies (NYSE: UBER), and Zoom Communications (NASDAQ: ZM). |
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to KnowThe latest trading day saw Astrazeneca (AZN) settling at $66.58, representing a -0.09% change from its previous close. |
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-TermWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
Why Is AstraZeneca PLC (NASDAQ:AZN) Among the Best FTSE Dividend Stocks to Buy Now?We recently compiled a list of the 10 Best FTSE Dividend Stocks To Buy Now. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other FTSE dividend stocks. Goldman Sachs Research predicts moderate growth for the UK economy in 2025, with GDP rising 1.2%. That is slightly […] |
AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates with blockbuster potential. |
Better Buy: Novo Nordisk vs. AstraZenecaNovo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn't know it by looking at their stock market performances. AstraZeneca's shares are down by 2% over the trailing-12-month period, while Novo Nordisk's shares are in the red by 14%. |
China’s NMPA prioritises HUTCHMED’s lung cancer therapy reviewHUTCHMED is set to gain a milestone payment from AstraZeneca. |
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and PfizerEli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog. |
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZNMonopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate. |
5 Large Drug Stocks to Keep An Eye On in the New YearR&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio. |